Search Results
10
Everything
Search Filters
Organization
AIM ImmunoTech Inc.
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 27, 2025 08:05 ET
|
AIM ImmunoTech Inc.
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the...
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
March 11, 2025 08:45 ET
|
AIM ImmunoTech Inc.
On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
February 28, 2025 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham...
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
February 26, 2025 13:20 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that...
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
February 26, 2025 08:30 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous...
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 25, 2025 08:30 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase...
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
February 11, 2025 08:45 ET
|
AIM ImmunoTech Inc.
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod)...
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
February 11, 2025 08:30 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
February 07, 2025 08:50 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant...
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 05, 2025 08:00 ET
|
AIM ImmunoTech Inc.
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...